# Merck & Co reported a first-quarter loss on Thursday, primarily due to acquisition-related charges.

*business · news · 2026-04-30 · Devdiscourse*

## Key points

- Merck's first-quarter revenue reached $16.3 billion, surpassing analyst expectations of $15.8 billion.
- The company's adjusted loss per share was $1.28, narrower than the expected $1.51 loss.
- A $3.62 per share charge from acquiring Cidara Therapeutics heavily impacted quarterly results.
- Full-year profit forecast now excludes Terns Pharmaceuticals' acquisition, which will add a $2.35 per share charge.
- Winrevair sales surged 88% while Keytruda sales rose 12% during the quarter.

**Companies:** Merck & Co
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3891958-merck-co-reports-narrower-loss-driven-by-strong-sales-in-keytruda-and-animal-health)

---

Canonical: https://newsio.io/n/6438f10c-c5df-413d-b929-76b2c52c6311/merck-co-reported-a-first-quarter-loss-on-thursday-primarily-due-to-acquisition
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works